In people with type 2 diabetes given lixisenatide 20 μg/day or placebo for 8 weeks, intragastric retention of a glucose drink at 240 min was much greater with lixisenatide than placebo (2 (0-11)% vs 48 (3-97)%; P < 0.0001).
In plain wordsIn people with type 2 diabetes, lixisenatide increased retention of a glucose drink in the stomach compared with placebo.
- Peptide
- Lixisenatide
- Outcome
- IncreaseIntragastric retention at 240 min
- Study
n: not reported in source
- Comparator
- Placebo
- Outcome group
- Gastrointestinal motility · Gastrointestinal
- Studied dose
- 20 μg/day · 8 weeksAs given in this study (human).
Measurements
- Intragastric retention at 240 min
- 48%
- lixisenatide; parenthetical range 3-97
- Intragastric retention at 240 min
- 2%
- placebo; parenthetical range 0-11
Source sentences
Intragastric retention at 240 min (2 (0-11)% vs 48 (3-97)%; P < 0.0001) was much greater with lixisenatide than placebo.
1 context sentence(design, population, supporting numbers)
Gastric emptying of a glucose drink was measured in people with type 2 diabetes given lixisenatide (20 μg/day or placebo) for 8 weeks.